Gilead Sciences stock: company signs Ebola drug licenses
Published on 11/17/2026 at 13:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEbola licensing expands access options
- Dr Reddy's Laboratories, Eva Pharma and Ferozsons Laboratories signed the agreements.
- Obeldesivir remains investigational and is not approved for filovirus post-exposure prophylaxis.
- Remdesivir licenses now include filovirus disease, subject to trial results and regulatory approvals.
RTT News reported on Tuesday, November 17, 2026, that Gilead Sciences had signed royalty-free voluntary licensing agreements with three generic manufacturers for its investigational antiviral obeldesivir. The arrangements are intended to support potential access to the drug as post-exposure prophylaxis for Ebola Bundibugyo virus disease.
Licenses cover investigational Ebola use
The manufacturers are Dr Reddy's Laboratories, Eva Pharma and Ferozsons Laboratories. Under the agreements, they are authorized to manufacture and supply obeldesivir across 127 licensed countries, subject to supporting clinical results and applicable regulatory approvals. The licensed territory includes all African countries that have reported cases in the current Ebola Bundibugyo outbreak.
Obeldesivir has been evaluated in clinical trials for COVID-19 and respiratory syncytial virus and has shown preclinical activity across multiple filoviruses, according to the report. It is being tested in the phase 3 EBO-PEP trial, a randomized, placebo-controlled field study of post-exposure prophylaxis for people at high risk of developing Ebola Bundibugyo virus disease.
The licensing agreements do not represent a marketing authorization. Obeldesivir is not approved for filovirus post-exposure prophylaxis in any country, so commercial supply depends on clinical evidence and regulatory decisions. Technology transfer discussions are under way, while additional manufacturers are being considered.
Remdesivir scope also expands
Gilead is also updating its existing voluntary licensing agreements for remdesivir to include filovirus diseases. The expanded arrangements could support access to remdesivir for Ebola Bundibugyo treatment, subject to positive results from the World Health Organization-sponsored PARTNERS trial and applicable approvals.
Remdesivir has been approved as a COVID-19 treatment in about 50 countries, but it is not approved for Ebola Bundibugyo disease and its effectiveness against that illness remains unproven. RTT News also reported that Gilead recently donated more than 2,000 vials of remdesivir to Kenya for investigational use involving Ebola treatment and post-exposure prophylaxis.
What the move means for investors
The agreements extend Gilead's potential role in the Ebola response beyond research into manufacturing and access planning. Their near-term financial significance remains tied to the clinical and regulatory path for both antivirals, while the royalty-free structure emphasizes access rather than immediate product revenue.
The S&P 500 provides the relevant U.S. market context for Gilead Sciences.
More news and analyses on Gilead Sciences stock
Gilead Sciences at a glance
- Company: Gilead Sciences
- ISIN: US3755581036
- Ticker: GILD
- Licensing focus: Investigational obeldesivir and expanded remdesivir access for filovirus diseases
